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Rapamycin inhibits human renal epithelial cell proliferation:
Effect on cyclin D3 mRNA expression and stability.
Background. Recent data have suggested that rapamycin use
during the initial period after transplantation is associated with
prolonged delayed graft function (DGF). Because of the known
effects of rapamycin in other cell types, we speculated that
this action may be secondary to human renal epithelial cells
(HRECs) inhibition of proliferation.
Methods. Primary cultures of HRECs were incubated with
various concentrations of rapamycin. Cell proliferation was
evaluated by cytotoxicity assays. The cell cycle was analyzed
by flow cytometry. Protein expression levels were assessed by
Western blot. Cyclin D3 mRNA levels were measured by quan-
titative real-time polymerase chain reaction (PCR). The tran-
scriptional activity of the cyclin D3 gene was evaluated using
transient transfection.
Results. Rapamycin exerted a significant concentration-
dependent antiproliferative effect on growing HRECs by
inhibiting the G1 to S transition. The p70S6 kinase pathway lead-
ing to cell cycle progression was found to be active, and low
concentrations of rapamycin dramatically reduced p70S6 kinase
phosphorylation. Rapamycin completely inhibited the increase
in cyclin D3 protein expression and mRNA accumulation in-
duced by fetal calf serum, but did not affect cyclin E or cdk-
inhibitor expression levels. This regulation of cyclin D3 protein
expression is mainly due to a destabilization of its mRNA. Ra-
pamycin reduced the mRNA half-life by 26% (4.8 ± 1.3 hours
vs. 6.5 ± 1.0 hours, P < 0.001).
Conclusion. Rapamycin inhibits the proliferative response
of HRECs to mitogenic stimuli, and causes cell cycle arrest in
the early G1 phase, not only by a nonspecific process due to
inhibition of the p70S6k pathway, but also by a direct effect on
cyclin D3 mRNA stability.
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Rapamycin is a new potent immunosuppressive agent
used as an immunosuppressive drug [1]. Rapamycin acts
by inhibiting the proliferation and clonal expansion of
interleukin-2–stimulated T cells. When complexed with
FK-binding protein-12, its cellular receptor, rapamycin
binds to and inhibits the kinase activity of mTOR (mam-
malian target of rapamycin) [2], a central controller of
cell growth. In response to amino acids and growth fac-
tors, mTOR controls the mammalian translation ma-
chinery by activating the protein kinase p70S6 (p70S6k)
and inhibiting the eIF4E inhibitor 4E-BP1. Activation
of p70S6k and the resulting phosphorylation of the 40S
ribosomal protein S6 drive the mRNAs translation that
primarily encodes ribosomal proteins and components
of the translational apparatus. Thus, under favorable
growth conditions, phosphorylated p70S6k up-regulates
the translational machinery. TOR also phosphorylates
4E-BP1, a protein associated with the translation initi-
ation factor eIF4E. Phosphorylation of 4E-BP1 induced
by various mitogens releases 4E-BP1 from this complex,
allowing eIF4E to initiate the translation process [3].
EIF4E controls the translation of mRNAs such as the
transcripts encoding cyclin D1 and the c-myc oncogene
[3]. By inhibiting TOR, rapamycin reduces the transla-
tional process and arrests proliferating T-cell growth in
the mid-to-late G1 phase [4]. Rapamycin has also been
shown to block the G1 to S phase transition in other cell
types [5–7].
After renal transplantation, delayed graft function
(DGF), defined as the need for at least one hemodial-
ysis session during the first week after transplantation,
has been associated with both long-term and short-term
decrease of graft survival. DGF is secondary to ischemia-
reperfusion injury, and is associated with acute tubular
necrosis [8]. Recent data have shown that, despite the
absence of specific nephrotoxicity, rapamycin might in-
crease the prevalence, length, and severity of DGF when
used during the initial phase after transplantion [9–11].
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The rate of recovery of tubular cell function is thought to
depend on a balance between tubular cell death and the
ability of injured cells to enter the cell cycle and prolif-
erate [12, 13]. We therefore postulated that the negative
effect of rapamycin on recovery from DGF may be sec-
ondary to its antiproliferative action. Since this action
had never been reported in human renal epithelial cells,
the aim of this study was to investigate the effects of ra-
pamycin on cell proliferation, and to explore the mecha-
nisms of these effects, using human renal epithelial cells
(HRECs) in primary culture.
METHODS
Reagents and antibodies
Rapamycin was a gift from Wyeth Research
(Monmouth Junction, NJ, USA). All other chemi-
cals were obtained from Sigma-Aldrich (Saint Quentin
Fallavier, France). Rapamycin was diluted in ethanol. The
cell culture medium and the other cell culture products
were from Life Technologies (Cergy Pontoise, France).
Antibodies (Abs) specific for p16INK4 , cyclin D1, cy-
clin D2, cyclin D3, and cyclin E were purchased from
BD Biosciences (Le Pont de Claix, France). Phospho-
p70S6k (Thr389 and Thr421/Ser424) and total p70S6k Abs
were from Cell Signaling Technology (Saint Quentin
en Yvelines, France), and Abs specific for p21Cip1 and
p27Kip1 were from Santa Cruz Biotechnology (Le Perray
en Yvelines, France). Anti-actin Ab was obtained from
Sigma-Aldrich.
Cell culture methods
Normal human renal epithelial cells (HRECs) were
harvested from human nephrectomy specimens removed
for renal cell carcinoma, and isolated according to pre-
viously published methods, with minor modifications
[14, 15]. Fragments of nontumoral renal cortex were
minced and digested with collagenase IV (250 IU/mL)
for three hours at 37◦C. Cells were centrifuged and
the pellets washed three times with phosphate-buffered
saline (PBS). Cells were then cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5 lg/mL
insulin, 10 lg/mL human apotransferrin, 500 ng/mL hy-
drocortisone, 10 ng/mL EGF, 6.5 ng/mL triiodothyronin,
5 ng/mL sodium selenite, 1% fetal calf serum (FCS),
25 IU/mL penicillin, 25 lg/mL streptomycin, and 10
mmol/L HEPES buffer. Cells were then incubated at
37◦C in 5% CO2 and 95% air. The characterization of this
cellular model was performed by immunocytochemical
peroxydase analysis and flow cytometry analysis (data not
shown). Immunocytochemical analysis revealed a pos-
itive staining for cytokeratin (clone AE1/AE3) and a6
integrin (clone NKI-GoH3), two markers of epithelial
cells [16, 17], by the vast majority of cells, thus confirming
their epithelial nature. A small subset of cells also stained
positively for epithelial membran antigen (clone E29), a
marker of distal tubular and collecting duct cells [17], sug-
gesting their distal origin. FACS analysis showed a strong
staining for alanine aminopeptidase (CD13, clone WM-
47), a cell surface marker that distinguishes proximal
from distal tubular epithelial cells, but not from fibrob-
lasts [18], and the absence of staining for CD90 (clone
5E10), which is present on fibroblasts, but not on tubular
epithelial cells [19]. These results confirmed the proximal
descent of the vast majority of the cultured tubular ep-
ithelial cells. Experiments were not performed with cells
beyond the third passage because it has been shown that
no phenotypic changes occur up to this passage number
[20].
Cell proliferation and cytotoxicity assay
HRECs (103 cells/well) were seeded in 96-well plates,
starved for another 24 hours in serum-free medium, and
then treated with rapamycin and FCS. Six days later, the
relative number of living cells per well was determined on
the basis of mitochondrial integrity by assay with [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sul-fophenyl)-2H-tetrazolium (MTS) (Promega,
Charbonniers, France), according to the manufacturer’s
instructions.
Cell death was determined by measuring the amount of
lactate dehydrogenase (LDH) released into the medium
after treatment with rapamycin. LDH activity was deter-
mined by the CytoTox 96 non-radioactive cytotoxicity as-
say (Promega), and quantified by measuring absorbance
at 490 nm.
Protein isolation and Western blots
All experiments were done with subconfluent cells. In
all, 2 × 106 cells were washed once with cold PBS, har-
vested with a rubber policeman, and lysed for 30 minutes
at 4◦C in lysis buffer containing 10 mmol/L Tris-HCl (pH
7.5), 10% glycerol, 1% Triton X-100, 0.5% Nonidet P40,
1 mmol/L EDTA, 1 mmol/L EGTA, 150 mmol/L NaCl,
50 mmol/L NaF, 1 mmol/L sodium orthovanadate, and
a cocktail of protease inhibitors. Lysates were spun at
12,000 rpm for four minutes, and the supernatant was
collected. The protein concentration was assessed by the
bicinchoninic acid method (Pierce Chemicals, Rockford,
IL, USA).
Total protein extracts (50 lg/lane) were separated by
9% to 12% sodium dodecyl sulfate-polyacrylamide gel
electophoresis (SDS-PAGE) under denaturing and re-
ducing conditions and transferred to polyvinylidene fluo-
ride (PVDF) membrane (Amersham Pharmacia Biotech,
Orsey, France). Membranes were blocked for 1 hour
at room temperature with TTBS (20 mmol/L Tris, 150
mmol/L NaCl, and 0.1% Tween 20) containing 5% non-
fat dry-milk. Blots were incubated with the primary anti-
body for 1 hour at room temperature, or overnight at 4◦C,
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Table 1. Primer sequences used for real-time quantitative polymerase chain reaction
GenBank
RNAs accession number Primer sequences Fragment length
Human cyclin D3 mRNA NM001760 5′-TGGATGCTGGAGGTATGTG-3′ 205 bp
5′-CGTGGTCGGTGTAGATGC-3′
Human ribosomal protein L13a mRNA BC001836 5′-CCTGGAGGAGAAGAGGAAAGAGA-3′ 124 bp
5′-GAGGACCTCTGTGTATTTGTCAA-3′
18S rRNA K03432 5′-TCCCCCAACTTCTTAGAGG-3′ 234 bp
5′-CTTATGACCCGCACTTACTG-3′
and then for 30 minutes with a horseradish peroxidase-
conjugated secondary antibody (1/10,000 in TTBS).
Proteins were stained by chemoluminescence with the
enhanced chemiluminescence (ECL) system (Amersham
Pharmacia Biotech), followed by exposure to x-ray film.
Blots were then probed with an anti-actin polyclonal
antibody to check the amount of protein loaded onto
the gel.
Flow cytometry analysis
Cells were seeded in 100 mm dishes. At 50% con-
fluence, they were shifted to serum-free conditions for
24 hours. Cells were then incubated with 20 nmol/L ra-
pamycin for one hour, and stimulated with 10% FCS.
Eighteen hours later, they were labeled with 10 lmol/L
bromodeoxyuridine (BrdU) for one hour, harvested
by trypsinization, and washed once with PBS. Fixation
and permeabilization were performed according to the
BD Pharmingen BrdU Flow Kit staining protocol (BD
Pharmingen, Le Pont de Claix, France). After perme-
abilization, cells were incubated with 300 lg/mL DNAse
to expose incorporated BrdU, and then incubated for 20
minutes at room temperature in the dark with fluores-
cein isothiocyanate (FITC)-conjugated anti-BrdU anti-
bodies. Cells were resuspended with the fluorescent dye
7-amino actinomycin D for staining of total DNA. Up to
10,000 events/sample were analyzed. DNA was quanti-
fied by FACScan (Becton Dickinson, Franklin Lakes, NJ,
USA).
RNA isolation and cDNA synthesis
Total RNA was extracted from approximately 5 × 106
cells with the RNA Easy Midi Kit (Qiagen, Valencia,
CA, USA). Reverse transcription was performed on each
RNA sample (2 lg) using oligo dT and the High-Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions.
Quantitative real-time PCR
The mRNA levels of cyclin D3 were measured by
SYBR green real-time polymerase chain reaction (PCR),
and quantified using an ABI PRISM 7900 sequence de-
tector system (Applied Biosystems). Primers were used
to amplify a 205-base fragment of the human cyclin D3
gene mRNA (Table 1). This sequence was confirmed to
be specific to cyclin D3 mRNA (not homologous with the
other D-type cyclins mRNAs). Results were normalized
to the endogenous control human ribosomal protein L13a
mRNA for the study of the transcriptional activity of the
cyclin D3 gene, and to the 18S rRNA gene for the eval-
uation of the cyclin D3 mRNA half-life. Previous experi-
ments were conducted to test the impact of rapamycin
on 18S rRNA, and found no alteration of 18S rRNA
expression by rapamycin. We did not use an mRNA as
a endogenous control but a rRNA because 5,6-dichloro-
1b-D-ribofuranosylbenzimidazole (DRB) is known as a
specific inhibitor for RNA polymerase II transcription
[21]. It then affects the mRNA transcription, but has lim-
ited effect on rRNA, whose transcription is governed
by RNA polymerase I in eukaryotes [22]. DRB, thus,
allowed the analysis of the cyclin D3 mRNA expres-
sion profile and, finally, cyclin D3 mRNA half-life. Real-
time PCR was performed in triplicate reactions with 20
ng of cDNA in a final volume of 10 lL containing 1X
SYBR Green PCR Master Mix (Applied Biosystems)
and 300 nmol/L of both primers. Samples were heated
for 10 minutes at 95◦C, followed by 40 cycles of amplifi-
cation for 15 seconds at 95◦C, and 1 minute at 60◦C.
To compare the expression levels among different sam-
ples, the relative expression of cyclin D3 mRNA levels
was calculated using the comparative delta Ct (threshold
cycle number) method as described by Livak et al [23].
Plasmid, transfection, and luciferase assay
The cyclin D3 promotor-luciferase construct pGL3-
hCyclinD3 was generously provided by Dr. Cress
(Moffitt Cancer Center, FL, USA) [24]. The transcrip-
tional factor E2F1 expression plasmid pCMV-E2F1 was
kindly provided by Dr. Transy (INSERM UMR-S490,
Paris, France) [25, 26]. Plasmid DNA was prepared us-
ing QIAfilter columns (Qiagen).
For transfection of the reporter construct, 60 × 105
HRECs were seeded per well in 12-well plates. The next
day, cells were starved in serum-free medium for 24 hours.
They were then transfected with 1 lg of plasmid pGL3-
hCyclinD3 using the mixed lipofection reagent FuGene
6 (Roche Molecular Biochemicals, Meylan, France) at
a ratio of 6 lL of FuGene to 1 lg of DNA in serum-
free medium. In some experiments, 100 ng of the ex-
pression plasmid pCMV-E2F1 (or the corresponding
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empty expression vector pCMV) was cotransfected.
Twenty-four hours later, they were stimulated with FCS
in the presence or absence of 20 nmol/L of rapamycin
for 24 hours. After lysis of the cells in Reported Lysis
Buffer (Promega), luciferase content was quantified by
luciferase assay (Promega).
Statistical analysis
All data were expressed as mean ± SEM of three
different experiments, unless otherwise specified. Sta-
tistical significance was tested by nonparametric tests
(Mann Whitney U test for unpaired comparisons and
Wilcoxon test for paired comparisons). Relative densit-
ometric values were estimated using NIH Image 1.63
software (National Institutes of Health, Bethesda, MD,
USA). Statistical analyses were performed using Statview
5.0.1® software (Cary, NC, USA). P values of less than
0.05 were considered significant.
RESULTS
Rapamycin inhibits cell proliferation
We first evaluated the impact of increasing concentra-
tions of rapamycin on cell viability, and found that ra-
pamycin reduces viable cell numbers in a dose-dependent
manner compared to untreated cells (Fig. 1A). This
reduction occurred even with low concentrations of
rapamycin. At the concentration of 10 nmol/L, usually
observed in the blood of patients treated with rapamycin
in clinical practice, rapamycin reduced cell viability by up
to 40% compared to untreated cell viability (P < 0.05).
To establish whether this reduced viability resulted
from cell death or from decreased proliferation, we mea-
sured the amount of LDH released into the supernatant.
Such release occurs after cell death, whether the latter is
caused by necrosis or apoptosis. As shown in Figure 1B,
the total LDH content, indirectly reflecting the total cell
number, decreased in a dose-dependent manner. With 10
nmol/L rapamycin, the total LDH content decreased by
50% compared to untreated cells, confirming the result
observed with the cell proliferation assay (Fig. 1A). An
additional cytotoxic effect may be present with the higher
rapamycin concentrations because the LDH released in
the medium remained stable in spite of a decreased total
cell number.
When cell growth was stimulated with increasing con-
centrations of FCS, the antiproliferative effect of ra-
pamycin persisted. For all concentrations, the number of
cells decreased by 30% to 40% when they were incubated
with 20 nmol/L of rapamycin (Fig. 1C). The antiprolifer-
ative effect of rapamycin was not detectable in quiescent
cells cultured in a serum-free medium, even after 6 days.
This finding confirms that the decrease of cell viability in-
duced by rapamycin is secondary to its inhibition of cell
proliferation (Fig. 1C).
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Fig. 1. Inhibition of human renal epithelial cell proliferation by ra-
pamycin. (A and B) Serum-starved HRECs, seeded in 96-well plates,
were stimulated with complete medium containing 10% FCS in the pres-
ence of rapamycin concentrations ranging from 0 to 1000 nmol/L. After
incubation at 37◦C for six days, the relative number of living cells was
determined by the MTS assay in (A), and cytotoxicity was quantified
by LDH release into the culture medium (B). The effect of rapamycin
is expressed as % cell viability compared to untreated cells (A) ab-
sorbance at 490 nm (B). Results are expressed as mean ± SEM of 10
and eight independent experiments for (A) and (B), respectively. (C)
Serum-starved HRECs were stimulated for six days in medium con-
taining various concentrations of FCS, in the presence or absence of
20 nmol/L rapamycin. Cell viability was then measured and expressed
as% of viable cells compared to the maximum viability observed in un-
treated cells. Results are expressed as mean ± SEM of 3 independent
experiments. P values were evaluated vs. untreated cells: ∗P ≤ 0.05; ∗∗P
≤ 0.01.
Rapamycin inhibits G1 to S transition in cycling tubular
cells
To establish the effect of rapamycin on cycling HRECs,
the cell cycle was analyzed by flow cytometry, using
BrdU/7-AAD staining. Whereas after 36 hours of star-
vation in serum-free medium only 17.6 ± 4.0% of cells
were in the S/G2/M phases, stimulation with 20% FCS for
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Fig. 2. Rapamycin inhibits G1 to S transition in cycling human renal
epithelial cells. Serum-starved HRECs were stimulated with complete
medium containing 20% FCS, in the presence or absence of 20 nmol/L
rapamycin for 18 hours. Cell cycle was then analyzed after BrdU label-
ing as described in Methods (mean ± SEM of five independent experi-
ments). #P < 0.05 compared to FCS treated cells. §P < 0.05 compared
to starved cells.
18 hours caused significant cell entry into the cycle, with
34 ± 3.7% of cells in the S/G2/M phases (P = 0.0003).
When 20 nmol/L rapamycin was added in the culture
medium one hour before stimulation with FCS, the pro-
portion of cells that progressed from the G0/G1 to the
S/G2/M phase decreased significantly to 25.2 ± 8.0%
(P = 0.02) (Fig. 2). Conversely, when rapamycin was
added, the proportion of cells in the G0/G1 phases was
significantly higher than in untreated cells (71.2 ± 10.2%
vs. 60.9 ± 7.0%, P < 0.02). These results demonstrate that
rapamycin induces G1 phase arrest in cycling HRECs.
Rapamycin inhibits p70S6 kinase phosphorylation in nor-
mal human epithelial cells
Rapamycin treatment of mouse proximal tubular cells
was previously found to cause virtual abrogation of p70S6k
[21]. The activation of p70S6k by various mitogenic stim-
uli such as growth factors or nutrients requires phos-
phorylation at several serine and threonine residues. To
date, p70S6k activation has not been described in HRECs.
We therefore studied the phosphorylation of p70S6k at
two different sites in HRECs stimulated with 20% FCS,
with or without 20 nmol/L rapamycin, using Abs spe-
cific for p70S6k phosphorylated at threonine 389 and thre-
onine 421/serine 424. Figure 3A shows the kinetics of
p70S6k phosphorylation after mitogen stimulation. Low
levels of phosphorylation were observed in quiescent
cells. After stimulation, a rapid increase in phospholy-
lated p70S6k is observed at 60 minutes. Rapamycin added
before stimulation totally inhibited p70S6k phosphoryla-
tion at all the time points measured (Fig. 3A). As shown in
Figure 3B, rapamycin concentrations as low as 1 nmol/L
inhibit the p70S6k phosphorylation in serum-stimulated
HRECs.
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Fig. 3. Rapamycin inhibits p70S6 kinase phosphorylation in normal
human epithelial cells. Serum-starved HRECs were stimulated with
complete medium containing 20% FCS, in the presence or absence of
rapamycin. The expression of phosphorylated p70S6k at two different
phosphorylation sites, and of total p70S6k, was evaluated by Western
blot, using specific polyclonal antibodies. Blots are representative of at
least three independent experiments, performed with cells from three
different kidneys. Cell extracts were prepared after serum stimulation
with or without 20 nmol/L rapamycin at the times indicated (A), or
stimulated with 20% FCS for three hours in the presence of various
concentrations of rapamycin (B), and then subjected to Western blot
analysis.
Rapamycin inhibits cyclin D3 protein expression in
proliferating tubular cells
The entry of quiescent cells (G0) into early G1 requires
the expression of D1, D2, and D3 cyclins. The level of cy-
clin E is increased in late G1, and is associated with cdk-2,
thereby playing a pivotal role in G1/S progression [28].
To determine whether rapamycin affects the expression
of cyclin D and/or cyclin E, total HRECs lysates were
subjected to Western blotting after stimulation with 20%
FCS with or without 20 nmol/L rapamycin. Rapamycin
dramatically reduced cyclin D3 expression in HRECs
(Fig. 4A and D), and almost completely inhibited the
FCS-induced increase in cyclin D3 expression. It may also
induce smaller inhibition of cyclin D1 expression, but did
not significantly affect the expression of cyclin D2 or cy-
clin E (Fig. 4). These results suggest that rapamycin might
cause cell cycle arrest in the early G1 phase by reducing
cyclin D protein expression.
p70S6k is a downstream regulator of the phosphatidyli-
nositol 3 (PI3) kinase signaling pathway [29]. In order
to explore if the effect of rapamycin on cyclin D3 ex-
pression is mediated by a linear pathway, we compared
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Fig. 4. Rapamycin prevents the serum-
stimulated increase in cyclin D proteins
during G1 progression. HRECs were de-
pleted of growth factors for 36 hours. They
were then stimulated with complete medium
containing 20% FCS, in the presence or
absence of 20 nmol/L rapamycin. Cell extracts
were prepared at the times indicated, and
subjected to SDS-PAGE. The level of protein
expression was visualized by Western blot.
(A) Representative Western blots of at least
four independent experiments, performed
with cells from three different kidneys. (B, C,
D, E) Cyclin levels were normalized against
actin (mean ± SEM of five independent
experiments). Cells were treated with vehicle
(black bars), or rapamycin (open bars). ∗P <
0.05.
the consequences on cyclin D3 expression of two specific
PI3-kinase inhibitors, LY294002 and wortmannin, and
of a treatment by rapamycin. LY294002 and rapamycin
completely prevented the FCS-induced increase in cyclin
D3 expression (Fig. 5). These data were considered PI3
kinase-specific, as these results were reproduced by wort-
mannin, which suppress in a dose-dependent manner the
FCS-induced cyclin D3 expression (Fig. 5). This similar ef-
fect of LY294002, wortmannin, and rapamycin suggested
a PI3 kinase/mTOR/p70S6k pathway-dependent regula-
tion of cyclin D3 expression.
Effect of rapamycin on cyclin-dependent kinase inhibitor
expression in proliferating tubular cells
Cyclin-cdk complexes are negatively regulated by cdk
inhibitors, which bind to and inhibit specific cyclin-cdk
complexes. Some of these inhibitors, such as p16INK4,
p21Cip1, and p27Kip1, are involved in the repression of G1
phase progression in many cell types. We found that 20
nmol/L rapamycin did not affect the expression of these
three inhibitors in proliferating HRECs (Fig. 6).
Effect of rapamycin on cyclin D3 mRNA in proliferating
epithelial cells
As cyclin D3 was the main cyclin affected by rapamycin
treatment, we then focused the study on this protein. It
has been previously shown in other cell types that ra-
pamycin may affect D-type cyclins expression by differ-
ent mechanisms [5]. It has been shown in other models
that rapamycin treatment not only delays the accumu-
lation of cyclin D1 mRNA during progression through
G1 in NIH 3T3 cells, but also affect stability of the tran-
script and accelerates the degradation of cyclin D pro-
tein [5]. Therefore, we first analyzed the transcriptional
activation of cyclin D3 mRNA. As shown in Figure 7A,
serum increased cyclin D3 mRNA levels, and treatment
of cells with rapamycin dramatically reduced the cy-
clin D3 mRNA accumulation. Noteworthy, 5 hours after
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Fig. 5. The inhibition by rapamycin of the serum-induced cyclin D3
protein is mediated by the PI3 kinase/mTOR/p70S6k pathway. Serum-
starved HRECs were stimulated with complete medium containing
20% FCS, in the presence or absence of 20 nmol/L rapamycin, or the
two PI3-kinase inhibitors LY294002 and wortmannin at the indicated
concentrations for 24 hours. Cell extracts were then prepared and sub-
jected to SDS-PAGE. The level of protein expression was visualized by
Western blot (mean ± SEM of five independent experiments).
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Fig. 6. Rapamycin does not affect cyclin-dependent kinase inhibitor
expression in HRECs. HRECs were depleted of growth factors for
36 hours. They were then stimulated with complete medium contain-
ing 20% FCS, in the presence or absence of 20 nmol/L rapamycin.
Cell extracts were prepared at the times indicated, and subjected to
SDS-PAGE. The level of protein expression was visualized by West-
ern blot. These Western blots are representative of five independent
experiments, performed with cells from three different kidneys.
stimulation, cyclin D3 mRNA levels increased similarly
in untreated and rapamycin-treated cells. This delayed ef-
fect of rapamycin suggests that this was not simply due to
a transcriptional inhibition. To distinguish between ef-
fects of rapamycin on transcription and on the stabil-
ity of the mRNA, quiescent HRECs were stimulated
as described above, and treated either in the presence
or the absence of the specific RNA polymerase II in-
hibitor DRB. The results obtained indicate that the sta-
bility of cyclin D3 mRNA is clearly affected by rapamycin
(Fig. 7B). Rapamycin reduced the cyclin D3 mRNA half-
life from more than 26% (4.8 ± 1.3 hours vs. 6.5 ±
1.0 hours, P < 0.001), suggesting an accelerated mRNA
degradation.
Effect of rapamycin on the transcriptional activity of the
human cyclin D3 gene
To explore the hypothesis of a transcriptional nature
of the control of the cyclin D3 gene expression by ra-
pamycin, we investigated the potential of its upstream
sequences to induce transcription in the HRECs in the
presence or absence of rapamycin. We used a plasmid
containing 1023 bp of the 5′-flanking region of the human
cyclin D3 gene (from −1017 to +6 relative to the ATG
codon at +1), cloned in front of a luciferase marker gene
[24], and analyzed using classic transient transfection as-
says. This upstream sequence of 1023 bp contains all of
the positive elements required for maximal transcription,
which are localized between nucleotides –366 and –167
[30]. As the transcription factor E2F1 is a well-recognized
transactivator of the cyclin D3 gene, an expression plas-
mid containing the E2F1 cDNA (or the corresponding
empty vector) was cotransfected as an internal positive
control. As expected from previous study, E2F1 [24] in-
duced the cyclin D3 transcriptional activity (Fig. 8). More-
over, increasing doses of rapamycin from 0 to 100 nmol/L
do not alter the effects of serum-stimulation on cyclin D3
transcriptional activity.
Effect of rapamycin on cyclin D3 protein stability in
cycling epithelial cells
As rapamycin has been suggested to accelerate the
degradation of cyclin D1 protein by the proteasome [5],
we studied the effect of rapamycin on cyclin D3 protein
half-life in HRECs. Quiescent HRECs were stimulated
as described above, and treated either in the presence or
the absence of the translation inhibitor cycloheximide.
Cyclin D3 protein level was evaluated by Western blot.
As shown in Figure 9, the protein half-life was about 1.6
hours and was not affected by rapamycin.
DISCUSSION
As far as we know, this work is the first to investigate
the antiproliferative effect of rapamycin on the growth
of normal HRECs in response to mitogenic stimuli, and
of its action on the signaling pathways that convey ex-
ternal growth signals to the machinery regulating the cell
cycle. We show here that, in HRECs: (1) rapamycin in-
hibits the proliferative response to mitogenic stimuli and
causes cell cycle arrest in the G1 phase; (2) this inhibitory
effect is associated with a specific inhibition of the cyclin
D3 expression; (3) this cyclin D3 expression inhibition is
partially independent of the inhibition of the p70S6k path-
way, but is secondary to a direct effect on cyclin D3 by
destabilizing its mRNA.
In a nonhuman cellular model, Lieberthal et al demon-
strated that rapamycin impaired recovery from acute re-
nal failure by blocking mouse tubular cell proliferation,
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Fig. 7. Effect of rapamycin on cyclin D3
mRNA accumulation and degradation in cy-
cling human renal epithelial cells. HRECs
were depleted of growth factors for 36 hours.
They were then stimulated with complete
medium containing 20% FCS, in the pres-
ence or absence of 20 nmol/L rapamycin.
Total RNA was prepared and cDNA were
synthetized for quantitative PCR analysis as
described in Methods. (A) Quantitation of
cyclin D3 mRNA levels. mRNA levels were
standardized against the mRNA amount be-
fore stimulation (mean ± SEM of three
independent experiments from three differ-
ent kidneys). (B) Effect of rapamycin on
cyclin D3 mRNA half-life. 5,6-dichloro-1b-
D-ribofuranosylbenzimidazole (DRB) (100
lmol/L) was added three hours’ post-
stimulation. Total RNA was then extracted at
the indicated time points for quantitative PCR
analysis. RNA levels are expressed as relative
to the level of expression before BRD addi-
tion (mean ± SEM of three independent ex-
periment from three different kidneys). ∗P <
0.05.
an effect that seems to be partly mediated by the inhibi-
tion of p70S6k [27], whose activity is essential for G1 cycle
progression [31]. We demonstrated here that rapamycin
inhibits both p70S6k activation and cell proliferation in
stimulated HRECs. Our findings suggest that p70S6k or
one of its downstream molecules plays a pivotal role in
cell cycle progression at the G0/G1 transition. Although
the role of rapamycin in this progression has been most
clearly established in mitogen-stimulated lymphocytes,
other human cell types are also potential targets for its
antiproliferative effects, including fibroblasts, endothelial
cells, smooth muscle cells, hepatocytes, and a broad range
of human tumor cell lines [5, 27, 32–36].
Rapamycin can block the G1 to S-phase transition of
the cell cycle. In HRECs, we demonstrate that rapamycin-
induced cell cycle arrest in the G1 phase is associated
with a dramatic reduction of cyclin D3 expression, and
of cyclin D1, to a smaller extent. This reduction was
not secondary to a general down-regulation of the pro-
teins involved in the G0/G1 to S-phase transition, be-
cause we could not detect any change in other cyclins
and cdk inhibitors expression. This regulation of cyclin
D3 by rapamycin seems to be tissue-specific because
rapamycin was found to be responsible for cyclin D3
down-regulation in a breast cancer cell line [37], in
primary cultures of spermatogonia [38], and in cycling
LLC-B cells [6], but did not affect cyclin D3 expression
in activated T cells [39]. We also show here that rapamycin
has no effect on the cdk inhibitor p27Kip1 in HRECs. This
result agrees with the results reported for other types of
epithelial cells [35, 40], whereas rapamycin was shown to
up-regulate p27Kip1 expression in T cells [6, 7]. Although
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Fig. 8. Rapamycin has no effect on the transcriptional activity of the
human cyclin D3 gene. HRECs were transiently transfected with a plas-
mid containing 1023 bp of the 5′-flanking region of the human cyclin
D3 gene (see Methods). Twelve hours later, cell cultures were serum-
stimulated in the presence of various amounts of rapamycin as indicated,
or with the solvent vehicle alone (ethanol 0.1% v/v) for 24 hours. Lu-
ciferase activity was assayed after 24 hours of serum stimulation. The
results were expressed relative to the luciferase activity measured in
the serum-stimulated sample (second bar), which was set arbitrarily at
100%. Results are expressed as luciferase activity, standardized against
the activity in cells treated with the rapamycin vehicle (mean ± SEM of
five independent experiment from five different kidneys). ∗∗P = 0.01.
all cells use the same repertoire of cyclins and CKIs, they
apparently regulate them differently, in a cell-type and
stimulus-specific manner [41].
We tried to determine the mechanism by which ra-
pamycin repress cyclin D3 in HRECs. We showed first
that the two unrelated specific PI 3-kinase inhibitors
LY294002 and wortmannin, on the one hand, and ra-
pamycin, on the other, inhibit similarly the serum-
induced cyclin D3 expression, suggesting that the effect
of rapamycin on p70S6k phosphorylation and cyclin D3
expression is mediated by the PI3-kinase/mTOR/p70S6k
pathway.
It has been previously reported in other cell types that
rapamycin may affect D-type cyclins expression by delay-
ing the accumulation of their mRNA during progression
through G1, but also by affecting stability of the transcript
and of the protein [5]. Unlike members of the cyclin fam-
ily, cyclins D1, D2, and D3 have a cell- and tissue-specific
pattern of expression and regulation [30, 42]. Since the
regulation of D-type cyclins is unknown in renal epithe-
lial cells, we studied the effect of rapamycin on the cyclin
D3 gene transcriptional activity, cyclin D3 mRNA accu-
mulation and stability, and cyclin D3 protein turnover.
Serum stimulation led to a rapid increase in cyclin D3
mRNA and protein [30]. Rapamycin also led to a de-
crease in cyclin D3 mRNA and protein accumulation.
This effect may be explained by an increased cyclin D3
mRNA turnover since rapamycin reduced by more than
25% the cyclin D3 mRNA half-life. Recent data have fo-
cused the role of TOR in the regulation of numerous gene
expressions at a post-transcriptional level in both yeast
and humans [43–45]. Indeed, the TOR pathway has been
shown to regulate mRNA turnover in the yeast Saccha-
romyces cerevisiae [43]. In human, rapamycin has been
shown to destabilize interleukin-3 (IL-3) mRNA in a mast
cell tumor line [44]. This effect has been attributed to the
presence in the 3′untranslated region (3′UTR) of the IL-3
transcript of an AU-rich element (ARE), IL-3 transcripts
lacking the AREs in the 3′UTR being resistant to ra-
pamycin treatment [44]. ARE are cis elements contained
within the 3′UTR of many short-lived mRNAs and con-
stitute repetitive AU motifs, which target the transcript
for rapid deadenylation and degradation [46]. Interest-
ingly, we found that the cyclin D3 mRNA carries in its
3′UTR two canonical AUUUA motifs. The destabilizing
effect of rapamycin on the cyclin D3 transcript is then
likely to be due to the presence of these AREs. Further
work will be required to confirm this hypothesis.
Serum stimulation led to a very similar increase of cy-
clin D3 protein and mRNA levels These data suggest
that serum induction of cyclin D3 expression does not
result only from enhanced translation of its mRNA in
HRECs, as previously proposed in other cell type [37].
Moreover, this parallelism between cyclin D3 mRNA and
protein regulation by rapamycin rules out the possibility
of an inhibition of the cyclin D3 mRNA translation by
rapamycin, as previously mentioned for an essential class
of mRNAs that contain an oligopyrimidine tract at their
transcriptional start (5′TOP), most notably mRNAs en-
coding ribosomal proteins and elongation factors [47].
Finally, using a reporter construct, we showed that ra-
pamycin had no effect on the transcriptional activity of
the cyclin D3 gene. Taken together, our results suggest
that the decrease by rapamycin of the cyclin D3 mRNA
and protein levels in serum-stimulated HRECs is due pri-
marily to post-transcriptional events such as stabilization
of the mRNA. However, we cannot formally rule out the
possibility that sequences outside of the 1023 bp construct
tested are required for transcriptional induction of the cy-
clin D3 gene.
In summary, We have shown that rapamycin inhibits
HRECs proliferation, and we have explored possible
mechanisms. These effects might be clinically relevant
because tubular lesions leading to DGF constitute a com-
mon complication after renal transplantation, and the
rate of recovery of tubular function depends on the abil-
ity of injured cells to enter the cell cycle and proliferate
[12]. Delayed graft function complicates post-transplant
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management, and increases both the duration of initial
hospital stay and the cost of hospitalization [48]. Al-
though conflicting conclusions have been reported about
the impact of DGF on the long-term outcome of renal
transplantation [49, 50], increasing evidence suggests that
DGF might influence long-term graft and patient sur-
vival [51, 52]. Recovery from ischemic acute renal fail-
ure requires the stimulation of tubular epithelial cell pro-
liferation by several cytokines and growth factors [12].
Agents that impair the ability of the renal epithelium to
proliferate may induce prolonged periods of acute re-
nal failure, or the failure of recovery [53]. In preclinical
studies, no substantial nephrotoxicity has been demon-
strated for rapamycin, and clinical trials in transplant pa-
tients also failed to show that it has any adverse effects
on the kidney, except for the exacerbation of renal in-
jury, when rapamycin is used together with calcineurin in-
hibitors [54]. However, recent clinical observations have
shown enhanced injury and delayed graft function recov-
ery when rapamycin is given at the time of transplanta-
tion [9, 10]. This apparent discrepancy suggests that ra-
pamycin only has harmful effects on tubular epithelial
cells when cell regeneration is needed to repair ischemic
injuries.
We demonstrate here that rapamycin has a significant
antiproliferative effect on human renal epithelial cells in
vitro, at concentrations of 0.1 nmol/L corresponding to
less than 0.1 ng/mL, which is below the usual blood con-
centrations observed in clinical pratice.
CONCLUSION
The present work is the first to demonstrate this an-
tiproliferative effect of rapamycin on cycling HRECs in
vitro. Rapamycin inhibits the proliferation of HRECs by
inducing cell cycle arrest in the G0/G1 phase. It inhibits
p70S6k activation in these cells, thereby blocking intracel-
lular signaling that leads to cell multiplication in response
to mitogenic factors. Moreover, unexpectedly, this an-
tiproliferative effect is not only mediated by a nonspecific
inhibition of the p70S6k pathway, but also by a direct ef-
fect of rapamycin on cyclin D3, a critical D-type cyclin for
the cell cycle progression into early G1, by a destabiliza-
tion of its transcript. This antiproliferative effect, which
is important for clinical effect on lymphocytes, may also
explain the prolongation of delayed graft function after
renal transplantation.
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